nach oben

Erschienen in:

01.03.2019 | Original Paper

Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients

verfasst von: Simin Ahmadvand, Zahra Faghih, Mehdi Montazer, Akbar Safaei, Maral Mokhtari, Peyman Jafari, Abdol-Rasoul Talei, Sedigheh Tahmasebi, Abbas Ghaderi

Erschienen in: Cellular Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In recent years, the prognostic/predictive significance of tumor infiltrating lymphocytes (TILs) has become a topic of interest. Here, we aimed to evaluate the prognostic significance of CD3+, CD8+, CD45RO+ and Foxp3+ TILs in breast cancer, as well as the relation of these markers to other clinicopathological features of this disease.

Methods

FFPE tumor samples from 94 females with invasive ductal carcinoma of the breast were retrospectively selected and immunohistochemically assessed for CD3, CD8, CD45RO and Foxp3 expression. Digital photos were acquired from the center (CT) and invasive margins (IM) of the tumors, after which positive cells were counted using ImageJ software.

Results

We found that greater infiltrations of target lymphocyte subpopulations were associated with TNM stage III, lymph node metastasis, high histological grade, ER negativity and HER2 positivity. The ratios of CD8+ cytotoxic T cells to CD3+, CD45RO+ and Foxp3+ TILs were found to be relatively higher in tumors exhibiting the aforementioned characteristics. In univariate survival analyses, CD8+ TILs in the IM and total CD45RO+ TILs were found to be significantly associated with overall survival (OS). Infiltration of CD45RO+ TILs in the CT and lymph node status were variables that significantly correlated with disease-free survival (DFS). Multiple Cox regression analyses revealed independent significant prognostic effects of total CD45RO+ TILs and lymph node status (HR of 3.24 and 3.19, respectively) in predicting OS. Infiltration of CD45RO+ TILs in the CT (HR 3.12) and lymph node status (HR 3.15) also exhibited significant prognostic effects on DFS.

Conclusion

From our data we conclude that CD45RO+ TILs serve as prognostic factors for predicting OS and DFS of breast cancer patients.

Nur mit Berechtigung zugänglich

L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. Oncoimmunology 65, 87–108 (2015)

G.K. Malhotra, X. Zhao, H. Band, V. Band, Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther 10, 955–960 (2010)CrossRefPubMedPubMedCentral

R.M. Tamimi, G.A. Colditz, A. Hazra, H.J. Baer, S.E. Hankinson, B. Rosner, J. Marotti, J.L. Connolly, S.J. Schnitt, L.C. Collins, Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 131, 159–167 (2012)CrossRefPubMed

X. Dai, T. Li, Z. Bai, Y. Yang, X. Liu, J. Zhan, B. Shi, Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 5, 2929–2943 (2015)PubMedPubMedCentral

P. Samadi, S. Saki, F.K. Dermani, M. Pourjafar, M. Saidijam, Emerging ways to treat breast cancer: Will promises be met? Cell Oncol 41, 605–621 (2018)CrossRef

D.F. Quail, J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423–1437 (2013)CrossRefPubMedPubMedCentral

P. Nilendu, S.C. Sarode, D. Jahagirdar, I. Tandon, S. Patil, G.S. Sarode, J.K. Pal, N.K. Sharma, Mutual concessions and compromises between stromal cells and cancer cells: Driving tumor development and drug resistance. Cell Oncol 41, 353–367 (2018)CrossRef

Q. Xu, C. Wang, X. Yuan, Z. Feng, Z. Han, Prognostic value of tumor-infiltrating lymphocytes for patients with head and neck squamous cell carcinoma. Cell Oncol 10, 10–16 (2017)

E.E. Paulsen, T. Kilvaer, M.R. Khanehkenari, R.J. Maurseth, S. Al-Saad, S.M. Hald, K. Al-Shibli, S. Andersen, E. Richardsen, L.T. Busund, R. Bremnes, T. Donnem, CD45RO(+) memory T lymphocytes—a candidate marker for TNM-Immunoscore in squamous non-small cell lung cancer. Neoplasia 17, 839–848 (2015)

10.

K. Hotta, M. Sho, K. Fujimoto, K. Shimada, I. Yamato, S. Anai, N. Konishi, Y. Hirao, K. Nonomura, Y. Nakajima, Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer 105, 1191–1196 (2011)CrossRefPubMedPubMedCentral

11.

J. Li, J. Wang, R. Chen, Y. Bai, X. Lu, The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget 8, 15621–15631 (2017)PubMedPubMedCentral

12.

R. Nejati, J.B. Goldstein, D.M. Halperin, H. Wang, N. Hejazi, A. Rashid, M.H. Katz, J.E. Lee, J.B. Fleming, J. Rodriguez-Canales, J. Blando, I.I. Wistuba, A. Maitra, R.A. Wolff, G.R. Varadhachary, H. Wang, Prognostic significance of tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemotherapy. Pancreas 46, 1180–1187 (2017)CrossRefPubMedPubMedCentral

13.

F. Pages, A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik, A. Kirilovsky, M. Nilsson, D. Damotte, T. Meatchi, P. Bruneval, P.H. Cugnenc, Z. Trajanoski, W.H. Fridman, J. Galon, Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353, 2654–2666 (2005)CrossRefPubMed

14.

J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pages, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoue, P. Bruneval, P.H. Cugnenc, Z. Trajanoski, W.H. Fridman, F. Pages, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006)CrossRefPubMed

15.

S. Ogino, K. Nosho, N. Irahara, J.A. Meyerhardt, Y. Baba, K. Shima, J.N. Glickman, C.R. Ferrone, M. Mino-Kenudson, N. Tanaka, G. Dranoff, E.L. Giovannucci, C.S. Fuchs, Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15, 6412–6420 (2009)CrossRefPubMedPubMedCentral

16.

F. Pages, A. Kirilovsky, B. Mlecnik, M. Asslaber, M. Tosolini, G. Bindea, C. Lagorce, P. Wind, F. Marliot, P. Bruneval, K. Zatloukal, Z. Trajanoski, A. Berger, W.H. Fridman, J. Galon, In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27, 5944–5951 (2009)CrossRefPubMed

17.

B. Mlecnik, M. Tosolini, A. Kirilovsky, A. Berger, G. Bindea, T. Meatchi, P. Bruneval, Z. Trajanoski, W.H. Fridman, F. Pages, J. Galon, Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29, 610–618 (2011)CrossRefPubMed

18.

J. Galon, F. Pages, F.M. Marincola, H.K. Angell, M. Thurin, A. Lugli, I. Zlobec, A. Berger, C. Bifulco, G. Botti, F. Tatangelo, C.M. Britten, S. Kreiter, L. Chouchane, P. Delrio, H. Arndt, M. Asslaber, M. Maio, G.V. Masucci, M. Mihm, F. Vidal-Vanaclocha, J.P. Allison, S. Gnjatic, L. Hakansson, C. Huber, H. Singh-Jasuja, C. Ottensmeier, H. Zwierzina, L. Laghi, F. Grizzi, P.S. Ohashi, P.A. Shaw, B.A. Clarke, B.G. Wouters, Y. Kawakami, S. Hazama, K. Okuno, E. Wang, J. O'Donnell-Tormey, C. Lagorce, G. Pawelec, M.I. Nishimura, R. Hawkins, R. Lapointe, A. Lundqvist, S.N. Khleif, S. Ogino, P. Gibbs, P. Waring, N. Sato, T. Torigoe, K. Itoh, P.S. Patel, S.N. Shukla, R. Palmqvist, I.D. Nagtegaal, Y. Wang, C. D'Arrigo, S. Kopetz, F.A. Sinicrope, G. Trinchieri, T.F. Gajewski, P.A. Ascierto, B.A. Fox, Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10, 205 (2012)

19.

C. Denkert, S. Loibl, A. Noske, M. Roller, B.M. Muller, M. Komor, J. Budczies, S. Darb-Esfahani, R. Kronenwett, C. Hanusch, C. von Torne, W. Weichert, K. Engels, C. Solbach, I. Schrader, M. Dietel, G. von Minckwitz, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28, 105–113 (2010)CrossRefPubMed

20.

R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, S. Wienert, G. Van den Eynden, F.L. Baehner, F. Penault-Llorca, E.A. Perez, E.A. Thompson, W.F. Symmans, A.L. Richardson, J. Brock, C. Criscitiello, H. Bailey, M. Ignatiadis, G. Floris, J. Sparano, Z. Kos, T. Nielsen, D.L. Rimm, K.H. Allison, J.S. Reis-Filho, S. Loibl, C. Sotiriou, G. Viale, S. Badve, S. Adams, K. Willard-Gallo, S. Loi, The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol 26, 259–271 (2015)CrossRefPubMed

21.

A.H. Lee, C.E. Gillett, K. Ryder, I.S. Fentiman, D.W. Miles, R.R. Millis, Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 48, 692–701 (2006)CrossRefPubMed

22.

A. Rody, U. Holtrich, L. Pusztai, C. Liedtke, R. Gaetje, E. Ruckhaeberle, C. Solbach, L. Hanker, A. Ahr, D. Metzler, K. Engels, T. Karn, M. Kaufmann, T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11, R15 (2009)

23.

A.M. Murri, M. Hilmy, J. Bell, C. Wilson, A.M. McNicol, A. Lannigan, J.C. Doughty, D.C. McMillan, The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer 99, 1013–1019 (2008)CrossRefPubMedPubMedCentral

24.

S. Aaltomaa, P. Lipponen, M. Eskelinen, V.M. Kosma, S. Marin, E. Alhava, K. Syrjanen, Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28, 859–864 (1992)CrossRef

25.

R. Matkowski, I. Gisterek, A. Halon, A. Lacko, K. Szewczyk, U. Staszek, M. Pudelko, B. Szynglarewicz, J. Szelachowska, A. Zolnierek, J. Kornafel, The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 29, 2445–2451 (2009)PubMed

26.

C. Carlomagno, F. Perrone, R. Lauria, M. de Laurentiis, C. Gallo, A. Morabito, G. Pettinato, L. Panico, T. Bellelli, A. Apicella, et al., Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology 52, 272–277 (1995)CrossRefPubMed

27.

S.B. Edge, C.C. Compton, The American joint committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17, 1471–1474 (2010)CrossRefPubMed

28.

S.M. Jackson, N. Harp, D. Patel, J. Zhang, S. Willson, Y.J. Kim, C. Clanton, J.D. Capra, CD45RO enriches for activated, highly mutated human germinal center B cells. Blood 110, 3917–3925 (2007)CrossRefPubMedPubMedCentral

29.

E. Krzywinska, A. Cornillon, N. Allende-Vega, D.N. Vo, C. Rene, Z.Y. Lu, C. Pasero, D. Olive, N. Fegueux, P. Ceballos, Y. Hicheri, M. Sobecki, J.F. Rossi, G. Cartron, M. Villalba, CD45 isoform profile identifies natural killer (NK) subsets with differential activity. PLoS One 11, e0150434 (2016)

30.

X. Fu, Y. Liu, L. Li, Q. Li, D. Qiao, H. Wang, S. Lao, Y. Fan, C. Wu, Human natural killer cells expressing the memory-associated marker CD45RO from tuberculous pleurisy respond more strongly and rapidly than CD45RO- natural killer cells following stimulation with interleukin-12. Immunology 134, 41–49 (2011)CrossRefPubMedPubMedCentral

31.

D. Aw, A.B. Silva, D.B. Palmer, Immunosenescence: Emerging challenges for an ageing population. Immunology 120, 435–446 (2007)CrossRefPubMedPubMedCentral

32.

T. Tian, M. Ruan, W. Yang, R. Shui, Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. Oncotarget. 7, 44395–44405 (2016)PubMedPubMedCentral

33.

S. Ladoire, L. Arnould, L. Apetoh, B. Coudert, F. Martin, B. Chauffert, P. Fumoleau, F. Ghiringhelli, Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14, 2413–2420 (2008)CrossRefPubMed

34.

K. Baker, J. Lachapelle, I. Zlobec, T.A. Bismar, L. Terracciano, W.D. Foulkes, Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58, 1107–1116 (2011)PubMed

35.

S. Loi, N. Sirtaine, F. Piette, R. Salgado, G. Viale, F. Van Eenoo, G. Rouas, P. Francis, J.P. Crown, E. Hitre, E. de Azambuja, E. Quinaux, A. Di Leo, S. Michiels, M.J. Piccart, C. Sotiriou, Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31, 860–867 (2013)CrossRefPubMed

36.

M.V. Dieci, M.C. Mathieu, V. Guarneri, P. Conte, S. Delaloge, F. Andre, A. Goubar, Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 26, 1698–1704 (2015)CrossRefPubMedPubMedCentral

37.

S. Loi, S. Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, P.L. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt, M.J. Piccart, S. Loibl, C. Denkert, M.J. Smyth, H. Joensuu, C. Sotiriou, Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 25, 1544–1550 (2014)CrossRefPubMed

38.

C. Solinas, L. Carbognin, P. De Silva, C. Criscitiello, M. Lambertini, Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. Breast 35, 142–150 (2017)CrossRefPubMed

39.

S. Luen, B. Virassamy, P. Savas, R. Salgado, S. Loi, The genomic landscape of breast cancer and its interaction with host immunity. Breast 29, 241–250 (2016)CrossRefPubMed

40.

A.N. Seo, H.J. Lee, E.J. Kim, H.J. Kim, M.H. Jang, H.E. Lee, Y.J. Kim, J.H. Kim, S.Y. Park, Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109, 2705–2713 (2013)CrossRefPubMedPubMedCentral

41.

S.J. Luen, R. Salgado, S. Fox, P. Savas, J. Eng-Wong, E. Clark, A. Kiermaier, S.M. Swain, J. Baselga, S. Michiels, S. Loi, Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: A retrospective analysis of the CLEOPATRA study. Lancet Oncol 18, 52–62 (2017)CrossRefPubMed

42.

Y. Vahidi, Z. Faghih, A.R. Talei, M. Doroudchi, A. Ghaderi, Memory CD4(+) T cell subsets in tumor draining lymph nodes of breast cancer patients: A focus on T stem cell memory cells. Cell Oncol 41, 1–11 (2018)CrossRef

43.

E.R. Pereira, D. Jones, K. Jung, T.P. Padera, The lymph node microenvironment and its role in the progression of metastatic cancer. Semin Cell Dev Biol 38, 98–105 (2015)CrossRefPubMedPubMedCentral

44.

F. Mehdipour, M. Razmkhah, A. Hosseini, M. Bagheri, A. Safaei, A.R. Talei, A. Ghaderi, Increased B regulatory phenotype in non-metastatic lymph nodes of node-positive breast Cancer patients. Scand J Immunol 83, 195–202 (2016)CrossRefPubMed

45.

Z. Faghih, S. Rezaeifard, A. Safaei, A. Ghaderi, N. Erfani, IL-17 and IL-4 producing CD8+ T cells in tumor draining lymph nodes of breast cancer patients: Positive association with tumor progression. Iran J Immunol 10, 193–204 (2013)PubMed

46.

Z. Faghih, N. Erfani, M.R. Haghshenas, A. Safaei, A.R. Talei, A. Ghaderi, Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol Lett 158, 57–65 (2014)CrossRefPubMed

47.

K. Enomoto, M. Sho, K. Wakatsuki, T. Takayama, S. Matsumoto, S. Nakamura, T. Akahori, T. Tanaka, K. Migita, M. Ito, Y. Nakajima, Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. Clin Exp Immunol 168, 186–191 (2012)CrossRefPubMedPubMedCentral

48.

O. Kawai, G. Ishii, K. Kubota, Y. Murata, Y. Naito, T. Mizuno, K. Aokage, N. Saijo, Y. Nishiwaki, A. Gemma, S. Kudoh, A. Ochiai, Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113, 1387–1395 (2008)CrossRefPubMed

49.

H.R. Ali, E. Provenzano, S.J. Dawson, F.M. Blows, B. Liu, M. Shah, H.M. Earl, C.J. Poole, L. Hiller, J.A. Dunn, S.J. Bowden, C. Twelves, J.M. Bartlett, S.M. Mahmoud, E. Rakha, I.O. Ellis, S. Liu, D. Gao, T.O. Nielsen, P.D. Pharoah, C. Caldas, Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 25, 1536–1543 (2014)CrossRefPubMed

50.

R. Yajima, T. Yajima, T. Fujii, Y. Yanagita, T. Fujisawa, T. Miyamoto, S. Tsutsumi, M. Iijima, H. Kuwano, Tumor-infiltrating CD45RO(+) memory cells are associated with a favorable prognosis breast cancer. Breast Cancer 23, 668–674 (2016)CrossRefPubMed

51.

L. Buisseret, S. Garaud, A. de Wind, G. Van den Eynden, A. Boisson, C. Solinas, Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology 6, e1257452 (2017)

Titel: Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients
verfasst von: Simin Ahmadvand
Zahra Faghih
Mehdi Montazer
Akbar Safaei
Maral Mokhtari
Peyman Jafari
Abdol-Rasoul Talei
Sedigheh Tahmasebi
Abbas Ghaderi
Publikationsdatum: 01.03.2019
Verlag: Springer Netherlands
Erschienen in: Cellular Oncology / Ausgabe 3/2019
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-019-00430-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C/EBP-homologous protein

Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma

Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges

Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer

Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie